title: Use of polyclonal/monoclonal antibody therapies in transplantation.
abstract: For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.
authors.affiliation: a Transplantation Research Center, Renal Division , Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States.
authors.forename: Melissa Y
authors.initials: MY
authors.lastname: Yeung
authors.affiliation: a Transplantation Research Center, Renal Division , Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States.
authors.forename: Steven
authors.initials: S
authors.lastname: Gabardi
authors.affiliation: a Transplantation Research Center, Renal Division , Brigham and Women's Hospital, Harvard Medical School , Boston , Massachusetts , United States.|b Faculty of Medicine, Professor of Medicine and Immunology , American University of Beirut , Beirut , Lebanon.
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: Sayegh
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D014180:Transplantation
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents
keywords: Acute cellular rejection; TOL101; Thymoglobulin; alemtuzumab; antibody mediated rejection; antithymocyte globulin; basiliximab; belimumab; eculizumab; induction therapy; monoclonal antibodies; rATG; rituximab; tocilizumab; transplant rejection; transplantation